All In Biotech

Drug Trial Radar · NCT05883449

Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL

A Phase 2, Open-Label, Multi-Center Study of Innate Cell Engager AFM13 in Combination With Allogeneic Natural Killer Cells (AB-101) in Subjects With Recurrent or Refractory Hodgkin Lymphoma and CD-30 Positive Peripheral T-Cell Lymphoma

Last checked: Nov 19, 2026Latest source record: Aug 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

25

Actual

Start

Oct 10, 2023

Primary completion

Nov 7, 2024

Study completion Jun 13, 2025

Sponsor

Lead sponsor
Affimed GmbHIndustry
Sponsor type
Industry
Collaborators
Artiva Biotherapeutics, Inc.
First posted
Jun 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

AFM13-203 is a phase 2, open-label, multi-center, multi-cohort study with a safety run-in followed by expansion cohorts. The study is evaluating the safety and efficacy of AFM13 in combination with AB-101 in subjects with R/R classical HL and CD30-positive PTCL.

Conditions

  • Relapsed or Refractory Hodgkin Lymphoma
  • Peripheral T Cell Lymphoma

Interventions

  • AFM13Drug

    anti-human CD30 × anti-human CD16A recombinant antibody therapy, intravenous infusion

  • AB-101Drug

    NK cell therapy, intravenous infusion

  • CyclophosphamideDrug

    Lymphodepleting chemotherapy, intravenous infusion

  • FludarabineDrug

    Lymphodepleting chemotherapy, intravenous infusion

  • Interleukin-2Drug

    Immune cytokine, subcutaneously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) by Independent Radiology CommitteeTime frame: Disease assessments were conducted on Day 43 (+- 3 days) of each cycle. All subjects were treated for a maximum of 3 cycles.

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • O'Neal Comprehensive Cancer Center at UAB

    Birmingham, Alabama

  • City of Hope National Medical Center

    Duarte, California

  • UC Irvine Health

    Orange, California

  • Sarah Cannon Research Institute

    Denver, Colorado

  • Norton Cancer Institute

    Louisville, Kentucky

  • Beth Israel Deaconess Medical

    Boston, Massachusetts

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Masonic Cancer Center, University of Minnesota

    Minneapolis, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • John Theurer Cancer Center

    Hackensack, New Jersey

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • UNC Immunotherapy Team, University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Cleveland Clinic

    Cleveland, Ohio

  • University of Pennsylvania, Abramson Cancer Center

    Philadelphia, Pennsylvania

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.